# Early Phase I Microdosing Study of ORM-14540 and ORM-12741

> **NCT00831077** · EARLY_PHASE1 · COMPLETED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 6 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ORM-14540
- **DRUG:** ORM-12741

## Key facts

- **NCT ID:** NCT00831077
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2009-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00831077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00831077, "Early Phase I Microdosing Study of ORM-14540 and ORM-12741". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00831077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*